A476060 Share Price Performance
₩13,780.00
9455.00 (218.61%)
Price ₩13,780.00
Share Price₩13,780.00
Onconic Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A476060 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Onconic Therapeutics Inc. Key Details
About A476060
- Founded
- 2020
- Employees
- 31
- CEO
- WebsiteView website
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.
